📰 Expanded Access Program News
Page 12 - Expanded Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expanded Access Program. Real-time updates on events, politics, business and more.
November 7, 2022
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...
November 7, 2022
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...
November 7, 2022
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...
November 4, 2022
Talicias efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI);...
November 3, 2022
/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...
November 3, 2022
/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...
November 3, 2022
Oral presentation will detail consolidated results from 81 patients with steroid-resistant, gastrointestinal, acute Graft-versus-Host-Disease (GI-aGvHD) treated with MaaT013 as salvage therapy, as part of an ongoing Early Access Program (EAP).Poster will present detailed results from the Phase 1b clinical trial of M...
October 20, 2022
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ --Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis. Financial Summary Telix reports total revenue of $55.3 million from global sales of Illuccix, up 168% on the previous quarter ($20.6 million, Q...
October 19, 2022
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental oxygen at...